There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PepGen Inc. (PEPG – Research Report) and Cidara Therapeutics (CDTX – Research Report) with bullish sentiments.
PepGen Inc. (PEPG)
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on PepGen Inc. today and set a price target of $26.00. The company’s shares closed last Wednesday at $6.03, close to its 52-week low of $4.32.
According to TipRanks.com, Fein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for PepGen Inc. with a $25.00 average price target.
See today’s best-performing stocks on TipRanks >>
Cidara Therapeutics (CDTX)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Cidara Therapeutics today and set a price target of $6.00. The company’s shares closed last Wednesday at $1.00.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Cidara Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PEPG:
- PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences
- PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference
- Is PEPG a Buy, Before Earnings?
- PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
- PepGen reports Q2 EPS (82c), consensus (81c)
